Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2440]

ASCO 2019: Novel targeted-antibody treatment produced responses in nearly half of patients with advanced urothelial cancer

ASCO 2019: Novel targeted-antibody treatment produced responses in nearly half of patients with advanced...

ASCO 2019: Use of broader criteria for clinical trial enrolment would double number of eligible patients with lung cancer

ASCO 2019: Use of broader criteria for clinical trial enrolment would double number of eligible patients with lung...

ASCO 2019: Adding enzalutamide to standard first-line treatment improves survival for men with metastatic hormone-sensitive prostate cancer

ASCO 2019: Adding enzalutamide to standard first-line treatment improves survival for men with metastatic hormone...

ASCO 2019: Drug targeting DNA damage response shows promise against cancers of anus and genitals

ASCO 2019: Drug targeting DNA damage response shows promise against cancers of anus and genitals

ASCO 2019: Patient groups untested in cancer immunotherapy trials found to also benefit

ASCO 2019: Patient groups untested in cancer immunotherapy trials found to also benefit

Lifting the lid on bladder cancer support

Lifting the lid on bladder cancer support

Study finds how prostate cancer cells mimic bone when they metastasise

Study finds how prostate cancer cells mimic bone when they metastasise

PSA, a prostate cancer marker, activates vascular and lymphangiogenic growth factors

PSA, a prostate cancer marker, activates vascular and lymphangiogenic growth factors

FDA approves avelumab plus axitinib for renal cell carcinoma

FDA approves avelumab plus axitinib for renal cell carcinoma

Pain management protocol sends 92% of cancer surgery patients home without opioids

Pain management protocol sends 92% of cancer surgery patients home without opioids

More from ecancer